Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 30, 2015. The report serves as a notification of transactions involving Directors and Persons Discharging Managerial Responsibilities (PDMRs) in accordance with Disclosure and Transparency Rule 3.1.4R(1)(c).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on equity transactions related to executive compensation.
- Share Price: The fair market value of an Ordinary Share at the point of vesting and sale on March 24, 2015, was £16.13.
Material Changes
The filing details the vesting of awards over Ordinary Shares made in 2012, 2013, and 2014 under the GlaxoSmithKline Share Value Plan (SVP). Specifically, it reports the following transaction for Mr. P C Thomson (Connected Person: Mrs. K Thomson):
- Shares Vested: 4,958 Ordinary Shares.
- Shares Sold: 2,332 Ordinary Shares sold to meet tax liabilities following the vesting.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a statutory disclosure of specific share transactions and does not contain forward-looking statements or risk assessments.
Investor Verification Checklist
- Verify the total number of shares held by Mr. P C Thomson and Mrs. K Thomson post-transaction.
- Confirm the tax rate applied to the sale of 2,332 shares to meet liabilities.
- Review the full terms of the GlaxoSmithKline Share Value Plan (SVP) for awards made in 2012, 2013, and 2014.
- Check for other PDMR transactions that may have been reported in separate filings during the same period.